



## OPEN ACCESS

## EDITED BY

Daniela Quaglino,  
University of Modena and Reggio Emilia, Italy

## REVIEWED BY

Luisa Morales-Nebreda,  
Northwestern University, United States  
Jennifer Speth,  
University of Michigan, United States  
Matthias Kugler,  
New York University, United States

## \*CORRESPONDENCE

Rachana R. Chandran,  
✉ rradhamanichandran@mednet.ucla.edu  
Daniel M. Greif,  
✉ daniel.greif@yale.edu

RECEIVED 08 November 2023

ACCEPTED 05 March 2024

PUBLISHED 20 March 2024

## CITATION

Chandran RR, Adams TS, Kabir I,  
Gallardo-Vara E, Kaminski N, Gomperts BN and  
Greif DM (2024), Dedifferentiated early  
postnatal lung myofibroblasts redifferentiate in  
adult disease.  
*Front. Cell Dev. Biol.* 12:1335061.  
doi: 10.3389/fcell.2024.1335061

## COPYRIGHT

© 2024 Chandran, Adams, Kabir, Gallardo-Vara,  
Kaminski, Gomperts and Greif. This is an open-  
access article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).  
The use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in this  
journal is cited, in accordance with accepted  
academic practice. No use, distribution or  
reproduction is permitted which does not  
comply with these terms.

# Dedifferentiated early postnatal lung myofibroblasts redifferentiate in adult disease

Rachana R. Chandran<sup>1,2,3\*</sup>, Taylor S. Adams<sup>4</sup>, Inamul Kabir<sup>1,2</sup>,  
Eunate Gallardo-Vara<sup>1,2</sup>, Naftali Kaminski<sup>4</sup>,  
Brigitte N. Gomperts<sup>3,5,6,7,8</sup> and Daniel M. Greif<sup>1,2\*</sup>

<sup>1</sup>Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, CT, United States, <sup>2</sup>Department of Genetics, Yale University School of Medicine, New Haven, CT, United States, <sup>3</sup>Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, <sup>4</sup>Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States, <sup>5</sup>Children's Discovery and Innovation Institute, Mattel Children's Hospital, Department of Pediatrics, University of California, Los Angeles, Los Angeles, CA, United States, <sup>6</sup>Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, United States, <sup>7</sup>Eli and Edythe Broad Stem Cell Research Center, University of California, Los Angeles, Los Angeles, CA, United States, <sup>8</sup>Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, United States

Alveolarization ensures sufficient lung surface area for gas exchange, and during bulk alveolarization in mice (postnatal day [P] 4.5–14.5), alpha-smooth muscle actin (SMA)<sup>+</sup> myofibroblasts accumulate, secrete elastin, and lay down alveolar septum. Herein, we delineate the dynamics of the lineage of early postnatal SMA<sup>+</sup> myofibroblasts during and after bulk alveolarization and in response to lung injury. SMA<sup>+</sup> lung myofibroblasts first appear at ~P2.5 and proliferate robustly. Lineage tracing shows that, at P14.5 and over the next few days, the vast majority of SMA<sup>+</sup> myofibroblasts downregulate smooth muscle cell markers and undergo apoptosis. Of note, ~8% of these dedifferentiated cells and another ~1% of SMA<sup>+</sup> myofibroblasts persist to adulthood. Single cell RNA sequencing analysis of the persistent SMA<sup>-</sup> cells and SMA<sup>+</sup> myofibroblasts in the adult lung reveals distinct gene expression profiles. For instance, dedifferentiated SMA<sup>-</sup> cells exhibit higher levels of tissue remodeling genes. Most interestingly, these dedifferentiated early postnatal myofibroblasts re-express SMA upon exposure of the adult lung to hypoxia or the pro-fibrotic drug bleomycin. However, unlike during alveolarization, these cells that re-express SMA do not proliferate with hypoxia. In sum, dedifferentiated early postnatal myofibroblasts are a previously undescribed cell type in the adult lung and redifferentiate in response to injury.

## KEYWORDS

lung myofibroblasts, fate mapping, alveolarization, hypoxia, pulmonary hypertension, lung fibrosis

## 1 Introduction

During lung development, ~90% of the gas exchange surface area forms through alveolarization (Tschanz et al., 2014). In altricial species, such as humans and mice, alveolarization is predominantly a postnatal phenomenon and is bi-phasic, consisting of bulk (i.e., classical) and continued alveolarization (Hyde et al., 2007; Mund et al., 2008; Herring et al., 2014; Tschanz et al., 2014). In mice, bulk alveolarization is rapid, beginning at

postnatal day (P) 3 and continuing until P14. This rapid alveolarization occurs through septal eruption of the pre-existing immature septum formed during branching morphogenesis (Mund et al., 2008; Schittny, 2017). Conversely, continued alveolarization progresses slowly from P14 - P36 by the lifting off new septum from mature pre-existing septum (Mund et al., 2008; Tschanz et al., 2014; Rodríguez-Castillo et al., 2018; Rippa et al., 2021). During bulk alveolarization, elongated alpha-smooth muscle actin (SMA)<sup>+</sup> cells, called myofibroblasts, secrete elastin and collagen fibers in response to cues originating primarily from the adjacent epithelium, thereby generating the secondary septum to form alveoli (Lindahl et al., 1997; Branchfield et al., 2016; Schittny, 2017; Rippa et al., 2021; Zepp et al., 2021). SMA, encoded by the *Acta2* gene, is the most widely accepted marker for myofibroblasts and additional genes, such as *Aspn*, *Mustn1*, *Hhip* and *Tgfb1*, have recently also been described as markers of this population based on transcriptomic data (Xie et al., 2018; Negretti et al., 2021); however, for these latter genes, validation in terms of protein expression is lacking.

Platelet-derived growth factor receptor (PDGFR)- $\alpha^+$  mesenchymal cells are widely implicated as progenitors of myofibroblasts that express smooth muscle cell (SMC) markers SMA and SM22 $\alpha$ , and signaling through the PDGFA-PDGFR- $\alpha$  axis is essential for alveolarization (Lindahl et al., 1997; Bostrom et al., 2002; McGowan et al., 2008; Ntokou et al., 2015; Branchfield et al., 2016; Li et al., 2018). While PDGFR- $\alpha^+$  progenitor cell differentiation is critical for rapid generation of myofibroblasts during bulk alveolarization, it is not established whether proliferation of myofibroblasts plays a role in this process. In the context of bleomycin-induced lung fibrosis, our recent findings indicate that differentiated myofibroblasts are proliferative (Chandran et al., 2021). Moreover, in PDGFR- $\alpha^+$  cells isolated from the normal lung at P4, there is a positive correlation between expression levels of SMA and the proliferation marker Ki67(18). Importantly, after bulk alveolarization at  $\sim$  P15, SMA<sup>+</sup> lung myofibroblasts are close to undetectable (Branchfield et al., 2016). Whether alveolar myofibroblasts undergo apoptosis prior to P15 or dedifferentiate and persist to adulthood remains controversial (Kauffman et al., 1974; Schittny et al., 1998; Bruce et al., 1999; Li et al., 2018; Hagan et al., 2020). PDGFR- $\alpha$  marks SMA-myofibroblast progenitors in the embryonic and early postnatal lung and SMA<sup>+</sup> myofibroblasts during bulk alveolarization (Kimani et al., 2009; Ntokou et al., 2015; Branchfield et al., 2016; Li et al., 2018). Li and colleagues report that following lineage-labeling PDGFR- $\alpha^+$  cells between P1-P20, marked cells in the P40 lung are SM22 $\alpha^-$  and thereby, suggest that the PDGFR- $\alpha^+$  lineage persists in the adult lung in a dedifferentiated state (Li et al., 2018). On the other hand, a study utilizing *Fgf18-CreER<sup>T2</sup>* to label early postnatal myofibroblasts indicates apoptosis and clearance of these mesenchymal cells after alveolarization (Hagan et al., 2020). In support of this finding, a previous study shows substantial apoptosis of fibroblasts isolated from the rat lung after bulk alveolarization (Bruce et al., 1999).

Herein, our murine studies demonstrate that SMA<sup>+</sup> myofibroblasts are proliferative during bulk alveolarization, and that at the end of the second postnatal week, the majority of myofibroblasts downregulate SMC markers and then undergo apoptosis. However, a small percentage of the cells that downregulate SMC markers persist to adulthood. Single cell RNA

sequencing (scRNA-seq) of these persistent dedifferentiated cells reveals a transcriptomic signature that is unique from previously described lung fibroblasts. Interestingly, the dedifferentiated postnatal myofibroblasts in adult lungs, re-express SMA following hypoxia exposure or bleomycin-induced injury. Thus, we suggest that these dedifferentiated cells are a reserve population in the adult lung that is responsive to injury and may play an important role in subsequent lung remodeling.

## 2 Results


### 2.1 Early postnatal myofibroblasts accumulate and proliferate during bulk alveolarization

Alveolarization begins with septal eruption at P4 in the mouse lung (Mund et al., 2008). Myofibroblasts, elongated SMA<sup>+</sup> cells in the lung parenchyma distinct from vascular and airway SMCs, are the primary cell type implicated in laying down elastin in the alveolar septa during postnatal alveolarization (Bostrom et al., 1996; Lindahl et al., 1997; Choi, 2010; Branchfield et al., 2016). To study the dynamics of SMA<sup>+</sup> myofibroblast accumulation during alveolar septation, lungs were harvested from wild type mice at discrete time points in the early postnatal period until P30.5. Cryosections were stained for SMA and nuclei (DAPI). At P0.5, SMA expression was restricted to SMCs, and myofibroblasts were essentially not detectable in the lung parenchyma (Figures 1A, B). SMA<sup>+</sup> myofibroblasts initially appear at P2.5, markedly increase in number until they peak at P11.5, then subsequently decrease rapidly with less than half of the peak number of SMA<sup>+</sup> myofibroblasts observed at P14.5 and only very rare myofibroblasts discernible by P18.5 (Figures 1A, B; Supplementary Figure S1).

PDGFR- $\alpha^+$  progenitor cells have been shown to differentiate into postnatal SMA<sup>+</sup> myofibroblasts in the early postnatal lung (McGowan et al., 2008; Ntokou et al., 2015; Li et al., 2018). Although proliferation and differentiation are often inversely correlated (Ruijtenberg and van den Heuvel, 2016), prior studies suggest that differentiated (i.e., SMA<sup>+</sup>) myofibroblasts are proliferative (Kimani et al., 2009; Chandran et al., 2021). To determine whether SMA<sup>+</sup> lung myofibroblasts proliferate during bulk alveolarization, cryosections of lungs from wild type mice at P5.5 were stained for SMA and the proliferation marker Ki67 (Figure 1C). At this time point, 30%  $\pm$  2% of SMA<sup>+</sup> myofibroblasts are Ki67<sup>+</sup> (Figure 1D), suggesting that myofibroblast accumulation during bulk alveolarization results from myofibroblast proliferation, in addition to progenitor cell differentiation as indicated by earlier studies (Ntokou et al., 2015; Li et al., 2018).


### 2.2 Majority of early postnatal myofibroblasts dedifferentiate and undergo apoptosis

The reason for the disappearance of almost all SMA<sup>+</sup> myofibroblasts following bulk alveolarization is controversial. While some studies suggest apoptosis (Kauffman et al., 1974;



**FIGURE 1**

Myofibroblasts proliferate and then undergo apoptosis during bulk alveolarization. Lungs were harvested from postnatal mice at indicated ages, cryosectioned, and stained. **(A,C)** Sections from wild type mice were stained for SMA and in **(C)** for Ki67 as well. **(B)** The number of SMA<sup>+</sup> myofibroblasts per 0.03 mm<sup>3</sup> lung volume was quantified from sections as in **(A)**; n = 3 mice per time point. **(D)** Percent of SMA<sup>+</sup> myofibroblasts that were Ki67<sup>+</sup> was quantified, n = 3 mice, 5 sections per mouse and an average of 165 myofibroblasts per section. **(E–H)** *Acta2-CreERT2, ROSA26R(Zs/+)* mice were induced with 4-hydroxy-tamoxifen (4-OH TM) at P6.5, P8.5 and P10.5. Schematic is displayed in **(E)**. In **(F)** lung cryosections were stained with the TUNEL assay and imaged for Zs (fate marker). Close-ups of boxed regions are shown below. In **(G,H)** the percent of Zs<sup>+</sup> cells that are TUNEL<sup>+</sup> and the number of Zs<sup>+</sup> cells per microscopic field were quantified, respectively; n = 3 mice per time point, 3 sections per mouse and an average of 14–271 Zs<sup>+</sup> cells per section were analyzed. One-way ANOVA with Tukey’s multiple comparison test was used with statistical significance vs. P0.5 in **(B)** and vs. P11.5 in **(G,H)**. ns,\*\*\*, \*\*\*\* indicate not significant, p < 0.001, p < 0.0001, respectively. Scale bars, 50 μm **(A,F)**, 25 μm **(C)**.



**FIGURE 2**

Select SMA<sup>+</sup> myofibroblasts downregulate smooth muscle cell markers and survive to adulthood. (A–C) *Acta2-CreERT2, ROSA26R(mTmG/+)* mice were induced with 4-OH TM at P6.5, P8.5 and P10.5, and lungs were harvested either at P11.5 or P60.5. Schematic is shown in (A). In (B) lung vibratome sections were stained for SMA, GFP (fate marker) and nuclei (DAPI). Open arrowhead indicates GFP<sup>+</sup>SMA<sup>+</sup> myofibroblast, and arrows with closed heads indicate GFP<sup>+</sup>SMA<sup>-</sup> dedifferentiated myofibroblasts. In (C) the number of GFP<sup>+</sup> cells per 3,000 nuclei that are SMA<sup>+</sup> or SMA<sup>-</sup> are quantified at P11.5 and P60.5; n = 4 mice per time point, 6 sections per mouse and on average 126 (for P11.5) or 5 (for P60.5) GFP<sup>+</sup> cells were quantified per section. Two-tailed Student's t-test was used. (D) Lungs were harvested from wild type mice at P11.5, and parenchymal cryosections were stained for SMA, nuclei (DAPI) and other markers as indicated; n = 6. (E) *Acta2-CreERT2, ROSA26R(mTmG/+)* mice were induced with 4-OH TM at P6.5, P8.5 and P10.5, and lungs were harvested at P60.5. Lung vibratome sections were stained for SMA, GFP and nuclei (DAPI) and other markers as indicated. Examples of both SMA<sup>+</sup> and SMA<sup>-</sup> cells are shown; n = 4–6. Scale bars 50 μm (B), 10 μm (D,E).

Schittny et al., 1998; Bruce et al., 1999; Hagan et al., 2020), others propose their persistence after downregulation of SMC markers (Li et al., 2018). To evaluate this issue in wild type mice, we immunostained lung sections at P11.5 and P14.5 for the apoptotic marker caspase-3. Surprisingly, although the lung has numerous caspase-3<sup>+</sup> apoptotic cells at P14.5, caspase-3<sup>+</sup>SMA<sup>+</sup> myofibroblasts were rarely detectable (Supplementary Figure S2A). Thus, we postulated that myofibroblasts downregulate SMA prior to undergoing apoptosis. To test this possibility, *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(Zs/+)</sup>* mice were induced with 4-hydroxy-tamoxifen (4-OH-TM) on P6.5, P8.5 and P10.5 to permanently label SMA<sup>+</sup> myofibroblasts and their lineage (Figure 1E). Note that, as *Acta2-CreER<sup>T2</sup>* utilizes an inducible Cre-loxP recombination system, expression of the lineage marker (in this manuscript, ZsGreen1 [Zs] or GFP) is retained permanently in lineage<sup>+</sup> cells even after expression of *Acta2* (encoding SMA) is downregulated. Lung cryosections at specific timepoints from P11.5-P30.5 were stained with terminal transferase dUTP-digoxigenin nick end-labeling (TUNEL) and DAPI and directly imaged for Zs (Figure 1F). At P11.5, very rare Zs<sup>+</sup> cells are TUNEL<sup>+</sup> (0.6% ± 0.1%; Figure 1G). Thereafter, there is a significant increase in this apoptotic cell percentage, peaking at P14.5 (21.6% ± 3.9%) and subsequently decreasing such that only rare Zs<sup>+</sup> cells are observed at P30.5 (Figure 1H). Although there is a significant reduction in the SMA<sup>+</sup> myofibroblasts between P11.5-P14.5, during this time period, the number of Zs<sup>+</sup> cells are unchanged, and the majority of TUNEL<sup>+</sup>Zs<sup>+</sup> cells are SMA<sup>-</sup> (Figure 1G; Supplementary Figures S2B, S2C) validating our hypothesis that dedifferentiation precedes apoptosis. Additionally, we noted Zs<sup>+</sup> signal within CD68<sup>+</sup> macrophages, suggesting the clearance of remnants of post-apoptotic myofibroblasts by macrophages (Supplementary Figure S3) (Hagan et al., 2020). Taken together, these findings suggest that at the end of bulk alveolarization, the majority of early postnatal myofibroblasts downregulate SMA (as well as other SMC markers; i.e., dedifferentiate) and then undergo apoptosis with the accumulated cell debris being cleared by macrophages.

### 2.3 Select early postnatal myofibroblasts dedifferentiate and persist to adulthood

The staining for SMA and TUNEL and the fate mapping of SMA<sup>+</sup> cells (see Figure 1) suggest the presence of rare cells derived from the SMA<sup>+</sup> population that are TUNEL<sup>-</sup> and likely SMA<sup>-</sup> in the lung parenchyma at P30.5. Hence, we next sought to determine whether some of the early postnatal SMA<sup>+</sup> myofibroblasts dedifferentiate, and their lineage persists into adulthood. To this end, *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(mTmG/+)</sup>* pups were injected with 4-OH-TM at P6.5, P8.5 and P10.5, and lungs were harvested either at P11.5 to assess labeling efficiency or at P60.5 for lineage tracing (Figure 2A). Analysis of labeling efficiency indicates that 82% ± 1% of SMA<sup>+</sup> myofibroblasts are GFP<sup>+</sup> at P11.5 (Supplementary Figures S4A–S4C). SMA<sup>+</sup> myofibroblasts largely undergo apoptosis following bulk alveolarization, and at P60.5, rare GFP<sup>+</sup> cells persist in the lung (Figures 2B, C). These GFP<sup>+</sup> cells are primarily located in alveoli, distinct from arterioles or airways (Supplementary Figure


S4D). Indeed, ~9% of the total number of GFP<sup>+</sup> lung cells at P11.5 are present in the adult lung. At P60.5, of these persisted GFP<sup>+</sup> cells, 85% ± 4% are SMA<sup>-</sup> and the rest are SMA<sup>+</sup> (Figures 2B, C). These findings suggest that, after bulk alveolarization, >90% of the myofibroblasts undergo apoptosis but of the remaining myofibroblasts which do persist into adulthood, the vast majority are dedifferentiated.

Next, we evaluated the gene expression pattern of early postnatal SMA<sup>+</sup> myofibroblasts at the time of their peak abundance. For this analysis, *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(mTmG/+)</sup>* mice, which received 4-OH-TM at P6.5, P8.5 and P10.5, or wild type mice, were euthanized at P11.5. Lung cryosections were stained for SMA, nuclei (DAPI), cell population-specific markers and, in the case of *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(mTmG/+)</sup>* mice, for GFP as well (Figure 2D; Supplementary Figure S5A). At P11.5, SMA<sup>+</sup> myofibroblasts express other SMC markers, including, smooth muscle myosin heavy chain (SMMHC) and transgelin (SM22 $\alpha$ ), and mesenchymal markers, desmin and vimentin (Figure 2D). Known markers of SMA<sup>+</sup> myofibroblasts, such as asporin, mustin1 and transforming growth factor beta-induced (TGFBI) (Xie et al., 2018; Liu et al., 2021; Negretti et al., 2021), are also expressed (Figure 2D; Supplementary Figure S5A). However, markers of lipofibroblasts (adipose differentiation related protein [ADRP]), macrophages (CD68, sialic acid-binding immunoglobulin-like lectin F [Siglec-F]) and epithelium (prosurfactant protein C [proSPC]) were not detected (Supplementary Figure S5A).

Additionally, the expression pattern of the lineage derived from early postnatal myofibroblasts that persist to adulthood was analyzed. *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(mTmG/+)</sup>* mice were injected with 4-OH-TM on P6.5, P8.5 and P10.5, and immunohistochemistry of lung sections at P60.5 was performed to assess marker expression in GFP<sup>+</sup> cells that were also SMA<sup>+</sup> or SMA<sup>-</sup> (Figure 2E). SMMHC and SM22 $\alpha$  track with SMA expression. In contrast, both GFP<sup>+</sup>SMA<sup>+</sup> and GFP<sup>+</sup>SMA<sup>-</sup> cell types express neither desmin, vimentin, mustin1 and TGFBI but express neither CD68 nor ADRP (Figure 2D; Supplementary Figures S5B, S6, S7A, S7B). Of note, we found that mustin1 and TGFBI are also expressed in SMCs (Supplementary Figure S6). According to our previous study, PDGFR- $\beta$  is expressed in different subtypes of healthy lung fibroblasts (Chandran et al., 2021), and thus, we queried whether GFP<sup>+</sup>SMA<sup>+</sup> and GFP<sup>+</sup>SMA<sup>-</sup> cell populations express PDGFR- $\beta$ . Both cell populations exhibit heterogeneity in terms of PDGFR- $\beta$  expression, such that some of the SMA<sup>+</sup>GFP<sup>+</sup> cells and SMA<sup>-</sup>GFP<sup>+</sup> cells are PDGFR- $\beta$ <sup>+</sup> (Supplementary Figure S7C).

### 2.4 Single cell transcriptomic analysis of the lineage-traced, early postnatal myofibroblasts in adulthood

To evaluate the transcriptome of the lineage of early postnatal myofibroblasts in the adult lung, lineage labeled cells were analyzed by scRNA-seq. *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(Zs/+)</sup>* mice were injected with 4-OH TM on P6.5, P8.5 and P10.5 to label SMA<sup>+</sup> cells with Zs (Figure 3A). Mice were aged to P60.5 and euthanized, and lungs were harvested. Single cell lung suspensions were stained with DAPI,



and Zs<sup>+</sup>DAPI<sup>-</sup> live cells were isolated with fluorescence activated cell sorting (FACS). Isolated cells were then subjected to droplet-based single-cell sequencing (DropSeq), and transcriptomic data was

processed with Cell Ranger v3. Mouse transcriptome mm10 modified with the addition of the *ZsGreen1* gene sequence was used as the reference genome. Cell annotation and clustering

were performed based on the cell-specific transcriptional marker gene expression as described by Tsukui et al. (2020).

T-distributed stochastic neighbor embedding (t-SNE) was performed to visualize gene expression, and four clusters were defined (Figure 3B). Cluster 0 is composed of SMCs and peribronchial fibroblasts with the highest expression of SMC markers (*Acta2*, *Tagln*, *Myh11* and *Des*) and peribronchial fibroblast markers (*Hhip* and *Aspn*; Figures 3C, D). As expected, this cluster exhibits low expression of *Pdgfra*. Adventitial fibroblasts are represented by cluster 1 with high *Pdgfra*, *Ly6a* and *Col1a1* (Figures 3C, D). This cluster is also enriched in *Col15a1* and *Adh7*. Clusters 2 and 3 are alveolar fibroblasts with high expression of *Pdgfra*, *Aspn* and *CD34* (Figure 3C). We identify cluster 3 as the rare cells of the lineage of early postnatal alveolar myofibroblasts that have remained SMA<sup>+</sup> and with representative cluster identity of *Acta2*<sup>+</sup>*Tagln*<sup>+</sup>*Pdgfra*<sup>+</sup>*Col6a3*<sup>+</sup>*Hhip*<sup>+</sup>*Mustn1*<sup>+</sup>*Dcn*<sup>+</sup> and cluster 2 as the lineage of early postnatal alveolar myofibroblasts that have downregulated SMA and with gene expression signatures of *Pdgfra*<sup>+</sup>*Col6a3*<sup>+</sup>*Col6a6*<sup>+</sup>*Acta2*<sup>+</sup>*Tagln*<sup>+</sup>*Hhip*<sup>-</sup>. Interestingly, cluster 2, but not cluster 3, is highly enriched in *Thbs4*, *Angptl1* and *Hmcn2* (Figure 3C), genes known to be involved in tissue remodeling (Feitosa et al., 2012; Carbone et al., 2018; Stenina-Adognravi and Plow, 2019a). The Thrombospondin 4 (Thbs4) transcript level is validated by immunohistochemistry for THBS4 (Supplementary Figure S7D).

To compare our results with published data, we integrated our scRNA-seq data with that of Tsukui et al. which encompasses lungs of healthy and bleomycin-treated adult mice (Tsukui et al., 2020) (Supplementary Figures S8A, S8B). Most Zs<sup>+</sup> cells from our dataset are located in peribronchial and adventitial fibroblast clusters from Tsukui et al. Possible explanations for this observation include: i) the lineage of early postnatal SMA<sup>+</sup> cells gives rise to adventitial and peribronchial fibroblasts; and/or ii) during the labeling time (P6.5-P10.5), adventitial and peribronchial fibroblasts express *Acta2*. Furthermore, SMA<sup>-</sup> alveolar fibroblasts from our scRNA-seq (located adjacent to adventitial fibroblast cluster in our data; Figure 3B), clustered in a small population within the adventitial fibroblast cluster from Tsukui et al. (Supplementary Figure S8B, right panel). Of note, there is not a single cell cluster exhibiting elevated expression of tissue remodeling genes *Thbs4*, *Angptl1*, *Hmcn2* in their data, but instead these genes are expressed at relatively high levels in alveolar, peribronchial or adventitial fibroblasts (Supplementary Figure S8C). Next, we examined whether these SMA<sup>-</sup> dedifferentiated cells derived from early postnatal myofibroblasts contribute to adult pathologies with substantial lung remodeling.

## 2.5 Dedifferentiated early postnatal SMA<sup>+</sup> cells contribute to hypoxia-induced myofibroblast accumulation


Although SMA<sup>+</sup> alveolar myofibroblasts are quite rare in the normal adult lung, they accumulate with exposure of mice to hypoxia (Chen et al., 2006; Sheikh et al., 2014). Thus, we interrogated whether dedifferentiated early postnatal SMA<sup>+</sup> cells re-express SMA and contribute to the pathological lung myofibroblast pool in hypoxic adult mice. To this end, *Acta2*-

*CreER*<sup>T2</sup>, *ROSA26R*<sup>(mTmG/+)</sup> mice were induced with 4-OH-TM on P6.5, P8.5 and P10.5, and then rested until P60.5, after which they were subjected to 21 days of normoxia or hypoxia to induce pulmonary hypertension and right ventricle hypertrophy (Figures 4A–C). Twelve hours prior to euthanasia, mice were injected intraperitoneally with 5-ethynyl-2'-deoxyuridine (EdU) to assess cellular proliferation. In the adult lung after hypoxia exposure, 31% ± 4% of the SMA<sup>+</sup> myofibroblasts are GFP<sup>+</sup> (Figures 4D, E), suggesting that ~ one-third of hypoxia-induced SMA<sup>+</sup> myofibroblasts originate from early postnatal myofibroblast redifferentiation (i.e., re-expression of SMA). Additionally, of the total GFP<sup>+</sup> cells in the parenchyma of the adult lung (excluding SMCs), 96% ± 3% are SMA<sup>+</sup> after hypoxia for 21 days as compared to 14% ± 2% under normoxic conditions (Figure 4F). Interestingly, GFP<sup>+</sup> alveolar cells were not proliferative under hypoxic conditions (Figures 4G, H). Furthermore, SMA<sup>+</sup> myofibroblasts in the hypoxic lung express *mustn1* (Supplementary Figure S9A), which is implicated as a myofibroblast marker (Xie et al., 2018; Negretti et al., 2021). Thus, a significant number of lineage<sup>+</sup> SMA<sup>-</sup> cells contribute to hypoxia-induced SMA<sup>+</sup> lung myofibroblasts predominantly by differentiation with limited, if any, proliferation.

## 2.6 Dedifferentiated early postnatal SMA<sup>+</sup> cells redifferentiate during bleomycin-induced lung fibrosis


To address whether this phenomenon is specific to hypoxia, the bleomycin lung injury model was used to study whether lineage<sup>+</sup> cells contribute to accumulation of SMA<sup>+</sup> myofibroblasts and fibrosis in the lung (Liu et al., 2017). Most of these SMA<sup>+</sup> myofibroblasts form discrete thick interstitial patches in the lung (herein, referred to as interstitial myofibroblasts and the regions they occupy as fibrotic). However, some of the SMA<sup>+</sup> myofibroblasts are located in relatively normal appearing non-fibrotic alveolar regions (herein, these myofibroblasts are referred to as alveolar myofibroblasts and the regions they occupy as intact) and have an elongated morphology that is similar to alveolar SMA<sup>+</sup> myofibroblasts in the normal lung (Figure 5).

Previous studies from our group and others reported that pre-existing PDGFR-β<sup>+</sup> cells are the primary source of bleomycin-induced SMA<sup>+</sup> interstitial myofibroblasts, whereas adult SMA<sup>+</sup> cells provide a limited (maximum of ~10%) contribution (El Agha et al., 2017; Chandran et al., 2021). Additionally, some of the dedifferentiated elongated alveolar cells in the adult that derive from early SMA<sup>+</sup> cells are PDGFR-β<sup>+</sup> (see Supplementary Figure S7C). To investigate whether cells in the adult lung parenchyma that derive from early postnatal SMA<sup>+</sup> myofibroblasts give rise to pathological myofibroblasts during fibrosis, *Acta2-CreER*<sup>T2</sup>, *ROSA26R*<sup>(mTmG/+)</sup> mice were induced with 4-OH-TM on P6.5, P8.5 and P10.5 and then were or were not subjected to a single dose of orotracheal bleomycin at P60.5 (Figure 5A). Fourteen days later, lungs were harvested, and sections were stained for SMA, GFP and nuclei (DAPI) and quantified (Figures 5A–C). After bleomycin exposure, in non-fibrotic intact lung regions, 42% ± 5% SMA<sup>+</sup> myofibroblasts were GFP<sup>+</sup> cells, whereas in fibrotic regions,



**FIGURE 4**  
 Dedifferentiated early postnatal SMA<sup>+</sup> cells redifferentiate upon hypoxia exposure in the adult lung. *Acta2-CreERT<sup>2</sup>, ROSA26R(mTmG/+)* mice were induced with 4-OH TM at P6.5, P8.5 and P10.5, rested until P60.5, exposed to hypoxia (FIO<sub>2</sub> 10%) or normoxia for 21 days, subjected to right ventricular systolic pressure (RVSP) measurements and then euthanized. Twelve hours prior to euthanasia, mice were injected with EdU. (A) Schematic of experimental set up. (B) RVSP was quantified as indicated. (C) The ratio of the weight of the right ventricle (RV) to that of the sum of left ventricle (LV) and septum (S) was measured. n = 3 mice for each group. (D) Lung cryosections were stained for SMA, GFP (fate marker) and nuclei (DAPI). n = 4 mice per group. Open arrowheads indicate GFP<sup>+</sup>SMA<sup>+</sup> cells and arrows with closed heads indicate GFP<sup>+</sup>SMA<sup>-</sup> cells. (E) Percentage of SMA<sup>+</sup> cells that are GFP<sup>+</sup> was quantified; n = 4 mice, 5-8 sections per mouse, an average of 57 SMA<sup>+</sup> cells were quantified per section. (F) Percentage of GFP<sup>+</sup> cells that are SMA<sup>+</sup> was quantified; n = 4 mice, 5-8 sections per mouse, an average of 13 (normoxia) or 18 (hypoxia) GFP<sup>+</sup> cells were quantified per section. Two-tailed Student's t-test was performed. (G) Lung cryosections were stained for EdU, GFP (fate marker) and nuclei (DAPI). Open arrowheads indicate EdU<sup>+</sup> cells. (H) The percent of GFP<sup>+</sup> cells that are EdU<sup>+</sup> is quantified. For each treatment group, n = 4 mice, 6 sections per mouse, average 15 (normoxia) or 16 (hypoxia) GFP<sup>+</sup> cells per section quantified; ns, not significant. Scale bars, 100 μm (D), 50 μm (G).






among interstitial myofibroblasts this contribution was  $11\% \pm 4\%$ , which is similar to that seen following adult *Acta2* lineage labeling (Chandran et al., 2021) (Figures 5B, C). Furthermore, while only  $14\% \pm 1\%$  of GFP<sup>+</sup> cells are SMA<sup>+</sup> in the untreated normal lung,  $75\% \pm 3\%$  of GFP<sup>+</sup> cells are SMA<sup>+</sup> in the intact lung regions of the bleomycin-treated fibrotic lung (Figure 5D). Taken together, these findings suggest that the majority of persistent early postnatal dedifferentiated myofibroblasts redifferentiate during bleomycin-induced lung fibrosis to contribute to SMA<sup>+</sup> alveolar myofibroblasts in the intact lung regions, while not contributing to patchy fibrotic regions. Furthermore, SMA<sup>+</sup> myofibroblasts in intact regions of the lung parenchyma express *mustin1* with bleomycin injury (Supplementary Figure S9A), but, in comparison to SMA<sup>+</sup> cells

in fibrotic patches, they express low levels of collagen 1a1 (Supplementary Figure S9B).

### 3 Discussion

In this study, we describe the dynamics of alveolar myofibroblast accumulation and gene expression in the normal mouse lung during and after bulk alveologenesis and how, in adulthood, this lineage responds to injury (Figure 6). SMA<sup>+</sup> myofibroblasts initially appear in the lung at  $\sim$  P2.5, proliferate and rapidly accumulate, with their numbers peaking at  $\sim$  P11.5 (Figure 1). Consistent with previous reports (Bruce et al., 1999; Li et al., 2018; Hagan et al., 2020; Rippa



et al., 2021), over the next several days, these numbers are rapidly reduced. A group of studies suggest that myofibroblasts undergo apoptosis at the tail end of bulk alveolarization (Kauffman et al., 1974; Schittny et al., 1998; Bruce et al., 1999; Hagan et al., 2020). For instance, tamoxifen-induction of *Fgf18-CreER<sup>T2</sup>, ROSA26R-tdTomato* mice at P5-P8 demonstrates that tdTomato<sup>+</sup> alveolar myofibroblasts are cleared after the initial phase of rapid alveologenesi (Hagan et al., 2020). In contrast, the authors of a distinct study suggest the persistence of PDGFR- $\alpha$ <sup>+</sup> myofibroblasts into adulthood after downregulation of SMC markers (Li et al., 2018). In this latter study, the lineage of PDGFR- $\alpha$ <sup>+</sup> cells were marked by daily injection of doxycycline from P1-P20, and lungs were analyzed at P40. The presence of lineage marked cells that are almost exclusively SM22 $\alpha$ <sup>-</sup> at P40 was interpreted to indicate that PDGFR- $\alpha$ <sup>+</sup>SM22 $\alpha$ <sup>+</sup> cells downregulate SM22 $\alpha$  and persist (Li et al., 2018). An alternative explanation is the following: i) PDGFR- $\alpha$ <sup>+</sup>SM22 $\alpha$ <sup>+</sup> myofibroblasts undergo apoptosis by ~ P15; and ii) PDGFR- $\alpha$ <sup>+</sup>SMC marker<sup>-</sup> cells are labeled during the P15-20 time period, and cells of this lineage are present at P40. In light of this issue, we induced *Acta2-CreER<sup>T2</sup>, ROSA26R<sup>(mTmG/+)</sup>* mice with tamoxifen at P6.5, P8.5 and P10.5 to label and fate map cells that express SMA, a myofibroblast marker (Figure 2). Our results indicate that the vast majority of lineage marked cells downregulate SMA expression and then undergo apoptosis but a small minority of GFP<sup>+</sup> cells persist. Indeed, ~9% of the total number of lineage marked lung cells at P11.5 are present in the adult lung and 90% of these cells are dedifferentiated (i.e., SMA<sup>-</sup>).

SMA is the most extensively utilized myofibroblast marker, and no markers are completely specific to myofibroblasts. For instance, recent designations of *Tgfb1* and *Mustn1* transcripts as specific myofibroblast markers have not been validated at the protein level (Xie et al., 2018; Negretti et al., 2021). Indeed, our immunostaining data indicate that TGFBI and *mustn1* are also expressed in SMCs (Supplementary Figure S6). The myofibroblast transcriptome is highly dependent on the specific tissue, time point of development, maturation or aging and disease state analyzed. For instance, in PDGFR- $\alpha$ <sup>+</sup> cells of the normal lung, *Acta2* is almost

exclusively expressed in myofibroblasts at P7(26), which is included in the timeframe that we labelled SMA<sup>+</sup> cells for fate mapping. However, scRNA-seq of the developing lung at E17.5 indicates that *Acta2* is expressed across multiple mesenchymal cell populations (Liu et al., 2021). In addition, *Myh11* and *Tagln*, which are well described SMC markers, exhibit expression in myofibroblasts (Xie et al., 2018; Liu et al., 2021). Intermediate filament proteins vimentin and desmin are broadly expressed in mesenchymal cells, including multipotent mesenchymal stem cells (Lindahl et al., 1997; Mendez et al., 2010; Liu et al., 2013; Bagalad et al., 2017) and are also expressed in SMA<sup>+</sup> early postnatal myofibroblasts and SMA<sup>+</sup> and SMA<sup>-</sup> fate mapped cells in the adult lung (Figure 2). Taken together the results from our and others' studies, SMA reliably marks myofibroblasts and SMCs in the early postnatal lung.

Using *Acta2-CreER<sup>T2</sup>, ROSA26R<sup>(Zs/+)</sup>* mice and scRNA-seq, the transcriptomes of dedifferentiated (SMA<sup>-</sup>Zs<sup>+</sup>) and differentiated (SMA<sup>+</sup>Zs<sup>+</sup>) adult lung parenchymal cells that derive from the early postnatal SMA<sup>+</sup> cells were compared (Figure 3). Cluster 2 comprising dedifferentiated alveolar fibroblasts were characterized by expression of *Pdgfra*, *CD34* and *Aspn*. *Aspn* encodes asporin which interestingly is implicated in promoting TGF- $\beta$ -induced lung myofibroblast differentiation (Huang et al., 2022). This cluster also expresses *Thbs4*, *Angptl1* and *Hmgn2*, genes reputedly involved in tissue remodeling (Feitosa et al., 2012; Carbone et al., 2018; Stenina-Adognravi and Plow, 2019a). For instance, THBS4 regulates the production and assembly of collagen, and in the pathological context of cardiac pressure overload, THBS4 prevents excess ECM deposition and myocardial hypertrophy (Stenina-Adognravi and Plow, 2019b). In contrast to this dedifferentiated cluster, the SMA<sup>+</sup> alveolar myofibroblasts of cluster 3 express *Acta2*, *Tagln* and *Thbs1* and do not express the group of remodeling genes. Finally, the presence of cluster 1, identified as a subclass of adventitial fibroblasts, was unexpected in our dataset of cells derived from early postnatal SMA<sup>+</sup> cells. We put forth two possibilities for the appearance of this adventitial fibroblast cluster: 1) SMA<sup>+</sup> adventitial fibroblasts are present in the early postnatal lung and persist; or 2) SMA<sup>+</sup> cells in

the early postnatal lung transdifferentiate into adventitial fibroblasts during postnatal maturation or adulthood.

There are discrepancies, particularly in regard to the expression of markers within clusters, among published scRNA-seq datasets (Xie et al., 2018; Tsukui et al., 2020; Chandran et al., 2021; Liu et al., 2021; Negretti et al., 2021) and between these datasets and our data. For instance, Xie et al. and Liu et al. describe Hhip and Aspn as myofibroblast markers whereas the Aspn<sup>+</sup>Hhip<sup>+</sup> cluster is characterized as peribronchial fibroblasts in Tsukui et al. (Xie et al., 2018; Tsukui et al., 2020; Liu et al., 2021). As another example, Negretti et al. implicate Tgfb1 and Wnt5a as myofibroblast markers (Negretti et al., 2021); however, our results (Figure 3) indicate that Tgfb1 is expressed in all clusters, whereas Wnt5a was not detected in any of the clusters. Our protein analysis validates the expression of TGFBI in SMCs in addition to myofibroblasts (Supplementary Figure S6). The lack of Wnt5a expression may reflect that it is downregulated in our lineage labelled cells during the transition to adulthood and/or it expressed in a subset of myofibroblasts, distinct from those derived from early postnatal SMA<sup>+</sup> cells. In addition, the expression of Pi16 is restricted to the adventitial fibroblast cluster in results from Tsukui et al. (2020). Similarly, our data indicate that Pi16 is most upregulated in adventitial fibroblasts, yet it is also expressed SMA<sup>+</sup> and SMA<sup>-</sup> alveolar fibroblasts. Such inconsistencies complicate the identification and characterization of fibroblast subtypes and could stem from differences in experimental approach and analysis, including: i) age, strain, genotype of mice; ii) timing and dosage of tamoxifen; iii) tissue digestion protocol; iv) flow cytometric sorted or unsorted cells and method and duration of sorting; v) computational approaches, including, but not limited to, rigor in defining a cell population. It is also important to acknowledge that transcriptomic data does not necessarily reflect level of proteins. For example, Mustn1 transcript is lower in alveolar fibroblasts that are SMA<sup>-</sup> than those that are SMA<sup>+</sup> (Figure 3); however, there appears to be a similar expression of mustin1 at the protein level based on immunohistochemistry (Supplementary Figure S5).

In contrast to the identification by Tsukui et al. of expression of markers associated with peribronchial mesenchymal cells (Hhip, Aspn) and airway/vascular SMCs (Myh11, Acta2) in distinct clusters of scRNA-seq of the adult murine lung (Tsukui et al., 2020), our current (Figure 3) and previous (Chandran et al., 2021) scRNA-seq data do not reveal distinct expression of these markers. Instead, these markers are co-expressed in a single SMC/peribronchial fibroblast cluster (cluster 0 in Figures 3B, C). Notably, Xie et al. also did not report a distinct SMC cluster in their lung scRNA-seq analysis (Xie et al., 2018). Potentially our SMC/peribronchial cluster represents the “myofibroblast” cluster in Xie et al. (2018), expressing SMC markers as well as Hhip and Aspn and perhaps, the “peribronchial fibroblast” cluster in Tsukui et al. (2020). Another potential explanation for the hybrid phenotype of cluster 0 is that the current scRNA-seq analysis is limited to cells that are fate mapped from early postnatal SMA<sup>+</sup> cells and a small subset of these cells expressing markers of both peribronchial fibroblasts and SMCs are identified but may not be detected in a broader analysis. Alternatively, the hybrid phenotype may result from experimental conditions (e.g., cell dissociation bias, tamoxifen effects, or prolonged time in suspension during sample

processing due to FACS of Zs<sup>+</sup> cells). Interestingly, in a UMAP from Tsukui et al., peribronchial fibroblast and SMC clusters are in proximity, reflecting their similar gene expression patterns (Tsukui et al., 2020).

Our studies indicate that dedifferentiated myofibroblasts redifferentiate to express SMA in the adult lung in response to an altered oxygen environment or bleomycin exposure (Figures 4, 5). Notably, during hypoxia, the dynamics of SMA expression in these cells is reminiscent of alveolar myofibroblast progenitors during the initial stages of postnatal alveolarization: progenitors start as SMA<sup>-</sup> and by ~ P2.5, begin to express SMA, coincident with the change in oxygen levels following birth. With bleomycin exposure in the adult, dedifferentiated cells redifferentiate to give rise to myofibroblasts in intact lung regions but not in highly fibrosed areas of the lung. Our findings also reveal co-expression of collagen1a1 and SMA in fibrotic regions of the mouse lung whereas SMA<sup>+</sup> myofibroblasts in the non-fibrotic areas show in comparison, markedly reduced or no expression of collagen 1a1 (Supplementary Figure S9). Thus, there are limitations in using SMA as an indicator of cells with high collagen production (Sun et al., 2016). Interestingly, a recent study reports that PDGFR- $\alpha$ <sup>+</sup> cells are SM22 $\alpha$  - in the adult mouse lung, and bleomycin exposure after labeling this lineage in the adult results in lineage-tagged lung myofibroblasts (Li et al., 2018). Taking this work and our findings together suggests that the PDGFR- $\alpha$ <sup>+</sup> adult lung cells which do not derive from early postnatal SMA<sup>+</sup> alveolar myofibroblasts are likely to contribute to fibrotic foci.

Mechanisms underlying the accumulation of dedifferentiated cell-derived myofibroblasts in intact lung regions during bleomycin exposure are not elucidated, but we propose that the hypoxic environment of fibrotic lung regions may be inductive. Indeed, a hypoxia-inducible factor 1 $\alpha$  - pyruvate dehydrogenase kinase 1 signaling axis potentiates transforming growth factor (TGF)- $\beta$  induced differentiation of fibroblasts to myofibroblasts (Watanabe et al., 2014; Goodwin et al., 2018). Additionally, cytokines released during fibrogenesis, such as TGF- $\beta$  and interleukin-1 (Desmoulière et al., 1993; Shephard et al., 2004; She et al., 2021), may transform undifferentiated lung cells to myofibroblasts. Interestingly, under hypoxia, redifferentiated myofibroblasts are essentially not proliferative, which is in contrast to the substantial percentage of Ki67<sup>+</sup> alveolar myofibroblasts observed during early postnatal development (Figures 1, 4).

Finally, we speculate that dedifferentiated adult lung cells are specialized to respond to injury. This hypothesis gains support from studies with a pneumonectomy model, in which myofibroblasts have been implicated in playing an important role in re-alveolarization (Bennett et al., 2017; Ysasi et al., 2017). Additionally, as redifferentiated lineage<sup>+</sup> cells accumulate in intact lung regions during fibrosis (Figure 5), they likely have a distinct role from that of high collagen-producing myofibroblasts. The significance of this novel cell type that differentiates during adult lung pathologies is yet to be uncovered. A limitation of the study is the lack of mechanistic insights into the role of redifferentiation in pathogenesis of lung disease; however, designing and carrying out experimental studies to define these roles are quite challenging for a number of reasons. For instance, approximately one-third of hypoxia-induced lung myofibroblasts originate from early postnatal dedifferentiated myofibroblasts, and selectively

inhibiting redifferentiation of these cells would be very difficult *in vivo*. In addition, testing this hypothesis in cell culture poses major challenges due to difficulties in both isolation of this rare population of cells and in mimicking the *in vivo* pathological setting. The lung undergoes extensive remodeling under hypoxic and fibrotic conditions (Huang et al., 2013; Vadivel et al., 2014; Wang and Tang, 2020) and given the expression of genes implicated in tissue remodeling in the dedifferentiated cell cluster by scRNA-seq, it will be important in future studies to elucidate the role of redifferentiated myofibroblasts in lung remodeling post-injury.

## 4 Methods

### 4.1 Animals

All mouse experiments were performed in accordance with ethical regulations of the IACUC at Yale University. C57BL/6 wild type mice were used. *Acta2-CreER<sup>T2</sup>* mice have been described previously (Wendling et al., 2009). Cre reporters *ROSA26R<sup>(mTmG/mTmG)</sup>* and *ROSA26R<sup>(ZsGreen1/ZsGreen1)</sup>* were obtained from Jackson Laboratory (Muzumdar et al., 2007; Madisen et al., 2010). ZsGreen1 is abbreviated as Zs. Experiments utilized male and female mice.

### 4.2 Fate mapping, hypoxia and bleomycin treatment

For fate mapping experiments, *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(mTmG/+)</sup>* mice were injected intraperitoneally on P6.5, P8.5 and P10.5 with 65 µg/gm body weight of 4-OH-TM per day. At P60.5, mice were subjected to either hypoxia or bleomycin treatment. For hypoxia experiments, mice were housed in a rodent chamber with a calibrated oxygen controller and sensor (BioSpherix) and exposed to 10% FiO<sub>2</sub> (hypoxia) or room air (normoxia control) for 21 days. Right ventricular systolic pressure was measured by inserting a catheter into the right ventricle (RV) via the right jugular vein. Mice were sacrificed, and the lungs and heart were harvested. The weight ratio of the RV/(left ventricle + septum) was assessed as described earlier (Sheikh et al., 2014). Alternatively, to induce lung fibrosis, a single dose of bleomycin (1.5 U/kg body weight) was or was not (control) administered orotracheally. Fourteen days later, mice were euthanized, and lungs were harvested. From *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(mTmG/+)</sup>* mice, lung sections were stained for SMA, GFP and nuclei (DAPI). Contribution of the *Acta2-CreER<sup>T2</sup>* lineage to accumulated lung SMA<sup>+</sup> myofibroblasts in response to hypoxia or bleomycin was determined by scoring the percentage of myofibroblasts (parenchymal elongated SMA<sup>+</sup>DAPI<sup>+</sup> cells) that expressed lineage marker GFP. *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(Zs/+)</sup>* mice were utilized for scRNA-seq.

### 4.3 Lung preparation and immunohistochemistry

Mice were sacrificed by isoflurane inhalation, and the pulmonary vasculature was flushed by injecting phosphate buffered saline (PBS) through the RV. For vibratome sectioning, lungs were inflated by infusing 2% low-melting agarose through the trachea with an

angiocatheter. Harvested lungs were incubated in ice cold PBS for 30 min followed by Dent's fixative (4:1 methanol/dimethyl sulfoxide) overnight at 4°C, stored in 100% methanol at -20°C for a minimum of 2 days. For immunohistochemistry, lungs were bleached in 5% H<sub>2</sub>O<sub>2</sub> in methanol, followed by rehydration sequentially in 75%, 50% and 25% and 0% methanol in PBS. A vibratome was used to cut 150 µm thick sections. For preparing cryosections, lungs were fixed in 4% paraformaldehyde (PFA) overnight, washed and then incubated in 30% sucrose for at least 3 days. Lungs were then embedded in optical cutting temperature compound (OCT-Tissue Tek), frozen in dry ice and stored at -20°C or -80°C. A cryotome was used to cut 10–30 µm thick sections. For immunohistochemistry, vibratome or frozen sections were blocked in 5% goat serum in PBS containing 0.1% Triton X-100 (PBS-T), washed with PBS-T and incubated with primary antibodies at 4°C overnight. On the next day, sections were washed and incubated in secondary antibodies for 2 h. After washing in PBS-T, sections were mounted in fluorescence mounting medium (DAKO) or glycerol:methanol (1:1) mountant. Glycerol:methanol mountant was used to quench endogenous tomato fluorescence in the cryosections in studies using the mTmG reporter.

Primary antibodies used were chicken anti-GFP (1:100, Abcam), rat anti-CD68 (1:200, Biorad), rat anti-THBS4 (1:100, R&D), rabbit anti-desmin (1:200, Abcam), rabbit anti-vimentin (1:200, Abcam), rabbit anti-SM22α (1:500, Abcam), rabbit anti-SMMHC (1:100, Thermo Scientific-Alfa Aesar), rabbit anti-Ki67 (1:100, Invitrogen), rabbit anti-asperin (1:200, Abcam), rabbit anti-mustin1 (1:200, Abcam), rabbit anti-TGFBI (1:200, Abcam), rabbit anti-Pro-SPC (1:200, Abcam), rabbit anti-Siglec-F (1:200, Abcam), rabbit anti-ADRP (1:200, Abcam), rabbit anti-Coll1a1 (1:200, Cell Signaling), directly conjugated Cy3 anti-SMA (1:150–1:250, Sigma-Aldrich), and biotinylated anti-PDGFR-β (1:50, R&D). Elite ABC reagents (Vector Laboratories) and fluorescein tyramide system (PerkinElmer) were used to amplify biotinylated PDGFR-β staining as described previously (Chandran et al., 2021). Secondary antibodies were conjugated to either Alexa-488, -564, -647 fluorophores (1:250–500, Invitrogen). Nuclei were visualized with DAPI (1:1000, Sigma-Aldrich).

### 4.4 Proliferation of hypoxia-induced myofibroblasts derived from early postnatal SMA<sup>+</sup> cells

*Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(mTmG/+)</sup>* mice were injected with 4-OH-TM (65 µg/gm body weight per day) at P6.5, P8.5 and P10.5, and then starting at P60.5, mice were subjected to hypoxia for 21 days. Twelve hours prior to euthanasia, mice were injected intraperitoneally with 2.5 mg of 5-ethynyl-2'-deoxyuridine (EdU; Thermo Fisher Scientific). Lungs were harvested, fixed in 4% PFA overnight, permeabilized in 0.5% PBS-T for 30 min and stained with the Click-iT EdU Alexa Fluor Imaging Kit per instructions of the manufacturer (Thermo Fisher Scientific). Sections were co-stained for GFP and nuclei (DAPI). The percent of GFP<sup>+</sup> cells that express EdU were quantified.

### 4.5 TUNEL assay

TUNEL assay was performed using ApoptTag *in situ* apoptosis detection kit (Millipore-Sigma). Briefly, *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(Zs/+)</sup>*

mice were injected with 4-OH TM (200 µg per day) at P6.5, P8.5 and P10.5. Lungs were harvested on P11.5, P13.5, P14.5, P16.5 and P18.5 and P30.5 and fixed in 4% PFA. Cyrosections (10 µm) were treated with pre-cooled ethanol:acetic acid (2:1) for 5 min at -20°C and washed in PBS. Slides were then processed according to instructions of the manufacturer, culminating in incubation with anti-digoxigenin-rhodamine fluorochrome conjugate for 30 min at RT, protected from light. Sections were washed in PBS, mounted and directly imaged for Zs and rhodamine.

## 4.6 Single-cell RNA sequencing

### 4.6.1 Sample preparation and sequencing

Five *Acta2-CreER<sup>T2</sup>*, *ROSA26R<sup>(Zs/+)</sup>* mice were injected with 4-OH-TM (65 µg/gm body weight per day) at P6.5, P8.5 and P10.5. At P60.5, lungs were collected, minced and incubated at 37°C for 40 min in the enzyme mixture from Miltenyi Biotec Lung Dissociation Kit. During this incubation, tissue was subjected twice to gentle lung dissociation protocol in a gentleMACS dissociator (Miltenyi Biotec). After inhibiting enzymatic activity with 10% FBS, single cell suspensions from each mouse were pooled together and passed through a 100 µm cell strainer and centrifuged at 700 g for 10 min at 4°C. The pellet was washed in 1X PBS with 1% FBS, DAPI (nuclear stain) added to the cell suspension, and Zs<sup>+</sup>DAPI<sup>-</sup> cells were isolated by FACS. Trypan blue was used to aid in cell counting. The cells were pooled together in 0.04% bovine serum albumin in PBS and proceeded to library preparation and DropSeq. Construction of single cell 3' RNA-seq libraries and sequencing were undertaken as described previously (Chandran et al., 2021). Sequencing data was processed with Cell Ranger v 3.1.0. Mouse transcriptome mm10 that includes the sequence for the gene *ZsGreen1* was used as the reference genome.

### 4.6.2 Cell barcode clustering and annotation

All analyses were performed in R (version 3.6.1) using the package Seurat (version 3.1.0). UMI counts were scaled to 10,000 UMIs per cell, then natural log transformed with a pseudo-count of one  $\{\log[(TPM/100) + 1]\}$ . Feature selection, principal component analysis, neighbor embedding and Louvain modularity clustering were recursively performed on the data for the purpose of identifying clusters of discretely identifiable cell populations. Clusters were then annotated as either a multiplet population or known cell type by expert curation of transcriptional marker genes and concordance with the literature. Multiplets were identified as cell populations whose transcriptomic profile resembled a combination of two or more cell populations found in the data. Additionally, cells with less than 900 transcripts or greater than 10% mitochondrial transcripts were removed. Non-mesenchymal cell types were then discarded, based on expression hallmarks of epithelial (*Epcam*, *Cdh1*), endothelial (*Pecam1*, *Cdh5*, *Vwf*) or immune cells (*Ptprc*). The remaining 460 cells were used to generate t-SNE plots for visualizing gene expression. For this embedding, the top 1,000 variable genes were selected using Seurat's *FindVariableFeatures* implementation under default parameters, these genes were scaled and used for principal component analysis. The top 8 principal components were used with Seurat's *Run TSNE* implementation with the seed parameter equal to 7 to generate the figure.

## 4.7 Imaging

Images were acquired with Leica SP5 or SP8 confocal microscope or PerkinElmer UltraView Vox Spinning Disc confocal microscope. For image processing, analysis and cell counting, Volocity software (PerkinElmer), Adobe Photoshop and Adobe Illustrator were used.

## 4.8 Statistical analysis

Student's t-test or ANOVA with Tukey's multiple comparisons test were used for statistical analysis of the data (Prism 7 or 8 software). Significance threshold was set to be  $p < 0.05$ . Data are presented in box plot with distribution of individual n's and shown as mean ± standard deviation.

## Data availability statement

The original contributions presented in this study are included. Further inquiries can be directed to the corresponding authors. The scRNA-seq data presented in this study are deposited in the Gene Expression Omnibus repository accession number GSE252660.

## Ethics statement

The animal study was approved by the Yale University Institutional Animal Care and Use Committee. The study was conducted in accordance with the local legislation and institutional requirements.

## Author contributions

RC: Conceptualization, Project administration, Formal Analysis, Funding acquisition, Investigation, Methodology, Writing—original draft, Writing—review and editing. TA: Data curation, Formal Analysis, Investigation, Writing—review and editing. IK: Investigation. EG: Investigation, Writing—review and editing. NK: Resources, Writing—review and editing. BG: Resources, Funding acquisition, Writing—review and editing. DG: Conceptualization, Data curation, Funding acquisition, Project administration, Resources, Supervision, Writing—original draft, Writing—review and editing.

## Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Funding was provided by the Department of Army (W81XWH-18-1-0629 to DG), National Institute of Health (R35HL150766, R01HL125815, R01HL133016, R21NS088854 to DG and F32HL132532 to RC, UOHL153000 to BG), American Heart Association (Established Investigator Award, 19EIA34660321 to DG).

## Acknowledgments

We are grateful for Greif lab members and Gomperts lab members (Tammy Rickabaugh, Andrew Lund, Woosuk Choi, Chandani Sen) for their input on the experimental results and plans and the manuscript. We thank Kevin Boyen for technical experimental help. We also thank I. Weissman, D. Metzger and P. Chambon for mouse strains.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

- Bagalad, B. S., Mohan Kumar, K. P., and Puneeth, H. K. (2017). Myofibroblasts: master of disguise. *J. Oral Maxillofac. Pathol.* 21 (3), 462–463. doi:10.4103/jomfp.JOMFP\_146\_15
- Bennett, R. D., Ysasi, A. B., Wagner, W. L., Valenzuela, C. D., Tsuda, A., Pyne, S., et al. (2017). Deformation-induced transitional myofibroblasts contribute to compensatory lung growth. *Am. J. physiology. Lung Cell. Mol. physiology* 312 1, L79–L88–L88. doi:10.1152/ajplung.00383.2016
- Bostrom, H., Gritli-Linde, A., and Betsholtz, C. (2002). PDGF-A/PDGF alpha-receptor signaling is required for lung growth and the formation of alveoli but not for early lung branching morphogenesis. *Dev. Dyn.* 223 (1), 155–162. doi:10.1002/dvdy.1225
- Bostrom, H., Willetts, K., Pekny, M., Leveen, P., Lindahl, P., Hedstrand, H., et al. (1996). PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. *Cell.* 85 (6), 863–873. doi:10.1016/s0092-8674(00)81270-2
- Branchfield, K., Li, R., Lungova, V., Verheyden, J. M., McCulley, D., and Sun, X. (2016). A three-dimensional study of alveogenesis in mouse lung. *Dev. Biol.* 409 (2), 429–441. doi:10.1016/j.ydbio.2015.11.017
- Bruce, M. C., Honaker, C. E., and Cross, R. J. (1999). Lung fibroblasts undergo apoptosis following alveolarization. *Am. J. Respir. Cell. Mol. Biol.* 20 (2), 228–236. doi:10.1165/ajrcmb.20.2.3150
- Carbone, C., Piro, G., Merz, V., Simionato, F., Santoro, R., Zecchetto, C., et al. (2018). Angiopoietin-like proteins in angiogenesis, inflammation and cancer. *Int. J. Mol. Sci.* 19 (2), 431. doi:10.3390/ijms19020431
- Chandran, R. R., Xie, Y., Gallardo-Vara, E., Adams, T., Garcia-Milian, R., Kabir, I., et al. (2021). Distinct roles of KLF4 in mesenchymal cell subtypes during lung fibrogenesis. *Nat. Commun.* 12 (1), 7179. doi:10.1038/s41467-021-27499-8
- Chen, Y. F., Feng, J. A., Li, P., Xing, D., Zhang, Y., Serra, R., et al. (2006). Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling. *J. Appl. Physiol.* 100 (2), 564–571. doi:10.1152/jappphysiol.00595.2005
- Choi, C. W. (2010). Lung interstitial cells during alveolarization. *Korean J. Pediatr.* 53 (12), 979–984. doi:10.3345/kjp.2010.53.12.979
- Desmoulière, A., Geinoz, A., Gabbiani, F., and Gabbiani, G. (1993). Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. *J. Cell. Biol.* 122 (1), 103–111. doi:10.1083/jcb.122.1.103
- El Agha, E., Moiseenko, A., Kheirollahi, V., De Langhe, S., Crnkovic, S., Kwapiszewska, G., et al. (2017). Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. *Cell. Stem Cell.* 20 (2), 571–273. doi:10.1016/j.stem.2017.03.011
- Feitosa, N. M., Zhang, J., Carney, T. J., Metzger, M., Korzh, V., Bloch, W., et al. (2012). Hemicentin 2 and Fibulin 1 are required for epidermal–dermal junction formation and fin mesenchymal cell migration during zebrafish development. *Dev. Biol.* 369 (2), 235–248. doi:10.1016/j.ydbio.2012.06.023
- Goodwin, J., Choi, H., Hsieh, M. H., Neugent, M. L., Ahn, J. M., Hayenga, H. N., et al. (2018). Targeting hypoxia-inducible factor-1 $\alpha$ /pyruvate dehydrogenase kinase 1 Axis by dichloroacetate suppresses bleomycin-induced pulmonary fibrosis. *Am. J. Respir. Cell. Mol. Biol.* 58 (2), 216–231. doi:10.1165/ajrcmb.2016-0186OC
- Hagan, A. S., Zhang, B., and Ornitz, D. M. (2020). Identification of a FGF18-expressing alveolar myofibroblast that is developmentally cleared during alveogenesis. *Development* 147 (2), dev181032. doi:10.1242/dev.181032
- Herring, M. J., Putney, L. F., Wyatt, G., Finkbeiner, W. E., and Hyde, D. M. (2014). Growth of alveoli during postnatal development in humans based on stereological estimation. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 307 (4), L338–L344. doi:10.1152/ajplung.00094.2014
- Huang, S., Lai, X., Yang, L., Ye, F., Huang, C., Qiu, Y., et al. (2022). Asporin promotes TGF- $\beta$ -induced lung myofibroblast differentiation by facilitating rab11-dependent recycling of T $\beta$ RI. *Am. J. Respir. Cell. Mol. Biol.* 66 (2), 158–170. doi:10.1165/ajrcmb.2021-0257OC
- Huang, Y., Kapere Ochieng, J., Kempen, M. B., Munck, A. B., Swagemakers, S., van Ijcken, W., et al. (2013). Hypoxia inducible factor 3 $\alpha$  plays a critical role in alveolarization and distal epithelial cell differentiation during mouse lung development. *PLoS One* 8 (2), e57695. doi:10.1371/journal.pone.0057695
- Hyde, D. M., Blozis, S. A., Avdalovic, M. V., Putney, L. F., Dettorre, R., Quesenberry, N. J., et al. (2007). Alveoli increase in number but not size from birth to adulthood in rhesus monkeys. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 293 (3), L570–L579. doi:10.1152/ajplung.00467.2006
- Kauffman, S. L., Burri, P. H., and Weibel, E. R. (1974). The postnatal growth of the rat lung. II. Autoradiography. *Anat. Rec.* 180 (1), 63–76. doi:10.1002/ar.1091800108
- Kimani, P. W., Holmes, A. J., Grossmann, R. E., and McGowan, S. E. (2009). PDGF-Ralpha gene expression predicts proliferation, but PDGF-A suppresses transdifferentiation of neonatal mouse lung myofibroblasts. *Respir. Res.* 10 (1), 119. doi:10.1186/1465-9921-10-119
- Li, R., Bernau, K., Sandbo, N., Gu, J., Preissl, S., and Sun, X. (2018). Pdgfra marks a cellular lineage with distinct contributions to myofibroblasts in lung maturation and injury response. *Elife* 7. doi:10.7554/eLife.36865
- Lindahl, P., Karlsson, L., Hellstrom, M., Gebre-Medhin, S., Willetts, K., Heath, J. K., et al. (1997). Alveogenesis failure in PDGF-A-deficient mice is coupled to lack of distal spreading of alveolar smooth muscle cell progenitors during lung development. *Development* 124 (20), 3943–3953. doi:10.1242/dev.124.20.3943
- Liu, T., De Los Santos, F. G., and Phan, S. H. (2017). The bleomycin model of pulmonary fibrosis. *Methods Mol. Biol.* 1627, 27–42. doi:10.1007/978-1-4939-7113-8\_2
- Liu, X., Rowan, S. C., Liang, J., Yao, C., Huang, G., Deng, N., et al. (2021). Categorization of lung mesenchymal cells in development and fibrosis. *iScience* 24 (6), 102551. doi:10.1016/j.isci.2021.102551
- Liu, Y., Deng, B., Zhao, Y., Xie, S., and Nie, R. (2013). Differentiated markers in undifferentiated cells: expression of smooth muscle contractile proteins in multipotent bone marrow mesenchymal stem cells. *Dev. Growth and Differ.* 55 (5), 591–605. doi:10.1111/dgd.12052
- Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., et al. (2010). A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* 13 (1), 133–140. doi:10.1038/nn.2467
- McGowan, S. E., Grossmann, R. E., Kimani, P. W., and Holmes, A. J. (2008). Platelet-derived growth factor receptor-alpha-expressing cells localize to the alveolar entry ring and have characteristics of myofibroblasts during pulmonary alveolar septal formation. *Anat. Rec. Hob.* 291 (12), 1649–1661. doi:10.1002/ar.20764
- Mendez, M. G., Kojima, S.-I., and Goldman, R. D. (2010). Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. *FASEB J.* 24 (6), 1838–1851. doi:10.1096/fj.09-151639
- Mund, S. I., Stampanoni, M., and Schittny, J. C. (2008). Developmental alveolarization of the mouse lung. *Dev. Dyn.* 237 (8), 2108–2116. doi:10.1002/dvdy.21633

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

## Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcell.2024.1335061/full#supplementary-material>

- Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., and Luo, L. (2007). A global double-fluorescent Cre reporter mouse. *Genesis* 45 (9), 593–605. doi:10.1002/dvg.20335
- Negretti, N. M., Plosa, E. J., Benjamin, J. T., Schuler, B. A., Habermann, A. C., Jetter, C. S., et al. (2021). A single-cell atlas of mouse lung development. *Development* 148 (24), dev199512. doi:10.1242/dev.199512
- Ntokou, A., Klein, F., Dontireddy, D., Becker, S., Bellusci, S., Richardson, W. D., et al. (2015). Characterization of the platelet-derived growth factor receptor- $\alpha$ -positive cell lineage during murine late lung development. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 309 (9), L942–L958. doi:10.1152/ajplung.00272.2014
- Rippa, A. L., Alpeeva, E. V., Vasiliev, A. V., and Vorotelyak, E. A. (2021). Alveologenesis: what governs secondary septa formation. *Int. J. Mol. Sci.* 22 (22), 12107. doi:10.3390/ijms222212107
- Rodríguez-Castillo, J. A., Pérez, D. B., Ntokou, A., Seeger, W., Morty, R. E., and Ahlbrecht, K. (2018). Understanding alveolarization to induce lung regeneration. *Respir. Res.* 19 (1), 148. doi:10.1186/s12931-018-0837-5
- Ruijtenberg, S., and van den Heuvel, S. (2016). Coordinating cell proliferation and differentiation: antagonism between cell cycle regulators and cell type-specific gene expression. *Cell. Cycle* 15 (2), 196–212. doi:10.1080/15384101.2015.1120925
- Schittny, J. C. (2017). Development of the lung. *Cell. Tissue Res.* 367 (3), 427–444. doi:10.1007/s00441-016-2545-0
- Schittny, J. C., Djonov, V., Fine, A., and Burri, P. H. (1998). Programmed cell death contributes to postnatal lung development. *Am. J. Respir. Cell. Mol. Biol.* 18 (6), 786–793. doi:10.1165/ajrcmb.18.6.3031
- She, Y. X., Yu, Q. Y., and Tang, X. X. (2021). Role of interleukins in the pathogenesis of pulmonary fibrosis. *Cell. Death Discov.* 7 (1), 52. doi:10.1038/s41420-021-00437-9
- Sheikh, A. Q., Lighthouse, J. K., and Greif, D. M. (2014). Recapitulation of developing artery muscularization in pulmonary hypertension. *Cell. Rep.* 6 (5), 809–817. doi:10.1016/j.celrep.2014.01.042
- Shephard, P., Martin, G., Smola-Hess, S., Brunner, G., Krieg, T., and Smola, H. (2004). Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. *Am. J. Pathology* 164 (6), 2055–2066. doi:10.1016/S0002-9440(10)63764-9
- Stenina-Adognravi, O., and Plow, E. F. (2019a). Thrombospondin-4 in tissue remodeling. *Matrix Biol.* 75–76, 300–313. doi:10.1016/j.matbio.2017.11.006
- Stenina-Adognravi, O., and Plow, E. F. (2019b). Thrombospondin-4 in tissue remodeling. *Matrix Biol.* 75–76, 300–313. doi:10.1016/j.matbio.2017.11.006
- Sun, K. H., Chang, Y., Reed, N. I., and Sheppard, D. (2016).  $\alpha$ -Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGF $\beta$  activation or collagen production across multiple models of organ fibrosis. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 310 (9), L824–L836. doi:10.1152/ajplung.00350.2015
- Tschanz, S. A., Salm, L. A., Roth-Kleiner, M., Barre, S. F., Burri, P. H., and Schittny, J. C. (2014). Rat lungs show a biphasic formation of new alveoli during postnatal development. *J. Appl. Physiol.* 117 (1), 89–95. doi:10.1152/jappphysiol.01355.2013
- Tsukui, T., Sun, K. H., Wetter, J. B., Wilson-Kanamori, J. R., Hazelwood, L. A., Henderson, N. C., et al. (2020). Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. *Nat. Commun.* 11 (1), 1920. doi:10.1038/s41467-020-15647-5
- Vadivel, A., Alphonse, R. S., Etches, N., van Haaften, T., Collins, J. J., O'Reilly, M., et al. (2014). Hypoxia-inducible factors promote alveolar development and regeneration. *Am. J. Respir. Cell. Mol. Biol.* 50 (1), 96–105. doi:10.1165/ajrcmb.2012-02500C
- Wang, Z. N., and Tang, X. X. (2020). New perspectives on the aberrant alveolar repair of idiopathic pulmonary fibrosis. *Front. Cell. Dev. Biol.* 8, 580026. doi:10.3389/fcell.2020.580026
- Watanabe, T., Yasue, A., and Tanaka, E. (2014). Hypoxia-inducible factor-1 $\alpha$  is required for transforming growth factor- $\beta$ 1-induced type I collagen, periostin and  $\alpha$ -smooth muscle actin expression in human periodontal ligament cells. *Arch. Oral Biol.* 59 (6), 595–600. doi:10.1016/j.archoralbio.2014.03.003
- Wendling, O., Bornert, J. M., Chambon, P., and Metzger, D. (2009). Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. *Genesis* 47 (1), 14–18. doi:10.1002/dvg.20448
- Xie, T., Wang, Y., Deng, N., Huang, G., Taghavifar, F., Geng, Y., et al. (2018). Single-cell deconvolution of fibroblast heterogeneity in mouse pulmonary fibrosis. *Cell. Rep.* 22 (13), 3625–3640. doi:10.1016/j.celrep.2018.03.010
- Ysasi, A. B., Wagner, W. L., Valenzuela, C. D., Kienzle, A., Servais, A. B., Bennett, R. D., et al. (2017). Evidence for pleural epithelial-mesenchymal transition in murine compensatory lung growth. *PLOS ONE* 12 (5), e0177921. doi:10.1371/journal.pone.0177921
- Zepp, J. A., Morley, M. P., Loebel, C., Kremp, M. M., Chaudhry, F. N., Basil, M. C., et al. (2021). Genomic, epigenomic, and biophysical cues controlling the emergence of the lung alveolus. *Science* 371 (6534), doi:10.1126/science.abc3172